Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of RO7239361 (Taldefgrobep Alfa) in Healthy Volunteers
NCT03100630Phase 1Completed
- Sponsor
- Roche
- Start
- May 2017
- Primary completion
- Oct 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of taldefgrobep alfa in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Roche. Primary endpoints: Maximum Observed Serum Concentration up to 92 days, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration up to 92 days and 1 more. Started May 2017; status: completed.
02
Drugs
taldefgrobep alfa
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03100630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100630.